Ocera Therapeutics Reports Third Quarter 2015 Financial Results
04 nov. 2015 16h05 HE
|
Ocera Therapeutics, Inc.
STOP-HE Reaches 50% Enrollment; Expected Completion H2 2016 6 Accepted Abstracts at The Liver Meeting® 2015 Underscore the Potential Breadth of Therapeutic Application for OCR-002 ...
Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
05 oct. 2015 16h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
01 sept. 2015 16h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Tranzyme Pharma Announces Exercise of Underwriters' Over-Allotment Option and Closing of $11.5 Million Registered Direct Offering of Common Stock
18 sept. 2012 16h30 HE
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced that it has closed the previously announced underwritten registered direct offering of...